The Acquirers Podcast cover image

Andrew Summers of Summers Value Partners on healthcare, biotech $GILD, $QURE and $ELMD | S08 E02

The Acquirers Podcast

00:00

How Summers Approaches Biotech Risk

Andrew explains his de-risked, targeted biotech approach: avoid early-stage science and invest at phase III or approval stage.

Play episode from 10:42
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app